Physiomics Awarded New Contract by Numab

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG ("Numab Therapeutics").

This project reflects the continued application of Physiomics' modelling expertise across Numab Therapeutics' pipeline to accelerate the development of innovative therapies, building further on the already well-established relationship.

Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract, Physiomics will develop a pharmacokinetic-pharmacodynamic (PK/PD) model to inform the Target Candidate Profile of a key asset in Numab Therapeutics' Immunology and Inflammation pipeline. The modelling work is intended to support data-driven decision-making at an early stage of development and is expected to commence imminently, with completion anticipated within Q2 2026.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to continue our collaboration with Numab Therapeutics and to have the opportunity to contribute further insights across its promising pipeline. In particular, this work allows us to support earlier research and development decisions through quantitative, data-driven approaches, helping to shape candidate profiles at a critical stage and thus streamlining drug development journeys."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.